85.00
17.83%
-18.44
전일 마감가:
$103.44
열려 있는:
$82.72
하루 거래량:
53.47M
Relative Volume:
8.95
시가총액:
$377.54B
수익:
$39.36B
순이익/손실:
$13.79B
주가수익비율:
35.30
EPS:
2.4077
순현금흐름:
$9.83B
1주 성능:
-20.52%
1개월 성능:
-19.26%
6개월 성능:
-39.71%
1년 성능:
-16.10%
노보 노디스크 Stock (NVO) Company Profile
NVO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
85.00 | 377.54B | 39.36B | 13.79B | 9.83B | 3.086 |
LLY
Lilly Eli Co
|
767.76 | 690.46B | 40.86B | 8.37B | -2.28B | 9.25 |
JNJ
Johnson Johnson
|
144.47 | 347.83B | 87.70B | 14.68B | 19.03B | 6.05 |
ABBV
Abbvie Inc
|
175.58 | 310.27B | 55.53B | 5.12B | 15.62B | 2.88 |
MRK
Merck Co Inc
|
98.05 | 248.03B | 63.17B | 12.15B | 14.84B | 4.77 |
노보 노디스크 Stock (NVO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-05-30 | 개시 | Goldman | Buy |
2024-04-12 | 개시 | BMO Capital Markets | Outperform |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Neutral |
2023-12-01 | 개시 | Cantor Fitzgerald | Overweight |
2023-10-02 | 개시 | Argus | Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2022-07-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2022-06-28 | 다운그레이드 | UBS | Neutral → Sell |
2022-06-27 | 업그레이드 | Exane BNP Paribas | Underperform → Neutral |
2022-06-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-05-31 | 업그레이드 | Guggenheim | Neutral → Buy |
2022-04-25 | 업그레이드 | Cowen | Market Perform → Outperform |
2022-04-12 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2022-03-16 | 업그레이드 | Deutsche Bank | Hold → Buy |
2022-01-25 | 다운그레이드 | Liberum | Hold → Sell |
2021-12-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-12-17 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2021-01-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-09-29 | 개시 | Berenberg | Hold |
2020-07-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
2020-05-11 | 다운그레이드 | UBS | Buy → Neutral |
2020-05-04 | 개시 | Cowen | Market Perform |
2020-03-16 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2020-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-11-18 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-09-17 | 업그레이드 | Citigroup | Neutral → Buy |
2019-08-30 | 다운그레이드 | Jefferies | Hold → Underperform |
2019-06-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2019-06-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
2019-04-29 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2019-01-29 | 개시 | Exane BNP Paribas | Outperform |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2017-12-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
2017-12-06 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2017-12-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2017-09-25 | 다운그레이드 | Exane BNP Paribas | Outperform → Neutral |
2017-09-06 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
모두보기
노보 노디스크 주식(NVO)의 최신 뉴스
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally - The Motley Fool
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue - Barron's
Why Novo Nordisk A/S (NVO) Is the Best ADR Stock to Invest in? - Insider Monkey
12 Best ADR Stocks To Invest In According to Analysts - Insider Monkey
NVO Stock Quote Price and Forecast - CNN
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Novo Nordisk ADR (NYSE: NVO) Could Fell Another -55.9% - Stocks Register
Inside the Market Dominance of the Top 10 Pharma Giants - Value the Markets
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons - The Manila Times
10 Biggest Biotechnology Companies - Investopedia
Biopharma Stock Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges - Morningstar
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View - Yahoo Finance
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading - MSN
Novo Nordisk ADR earnings beat by $5.24, revenue topped estimates - Investing.com Australia
Thanks To Wall Street, Novo Nordisk Stock Is Now A Buy - Barchart
Globalization Isn’t in Decline. Here’s Why That Matters for Investors - Morningstar
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
India Subcutaneous Drug Delivery Devices Market Size & Outlook, 2030 - Grand View Research
Why this money manager sees FirstService, Novo Nordisk and Microsoft as good long-term holdings - The Globe and Mail
노보 노디스크 (NVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):